MARKERS OF HUMAN LYMPHOCYTE SUBPOPULATIONS IN PRIMARY IMMUNODEFICIENCY AND LYMPHOPROLIFERATIVE DISORDERS NLM AIDSLINE Important note: Information in this article was accurate in 1980. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


MARKERS OF HUMAN LYMPHOCYTE SUBPOPULATIONS IN PRIMARY IMMUNODEFICIENCY AND LYMPHOPROLIFERATIVE DISORDERS

Semin Hematol; 17(1):1-29 1980. Unique Identifier : AIDSLINE ICDB/80649672
Gupta S; Good RA; 1275 York Ave., New York, NY, 10021

Abstract: Recent developments concerning cell-surface and enzymatic markers of human lymphocyte subpopulations are reviewed, and the usefulness of these markers in defining human primary immunodeficiency and lymphoproliferative disorders is considered. Components of the immune system and the ontogeny of T and B cells are described. The following markers of human lymphoid-cell subpopulations are discussed: cytoplasmic and surface immunoglobulins; receptors for the crystallizable fragment (Fc) antibody fragment; receptors for complement components; receptors for human immune-region-associated (Ia)-like alloantigens; receptors for Epstein-Barr virus; receptors for mouse, Macaca monkey, Rhesus monkey, sheep, or autologous human RBCs; receptors for Helix pomatia; differentiation antigens; receptors for peanut agglutinin; and enzymatic markers. The usefulness of surface and intracellular markers in the definition, analysis, and manipulation of primary immunodeficiency disorders is described. Interactions of cellular and subcellular factors associated with immunodeficiency are discussed. Marker analysis of malignant proliferation of T and B cell lineage is discussed. The following types of cancer are included: acute lymphoblastic leukemia, chronic lymphocytic leukemia, Sezary syndrome, hairy cell leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma. (291 Refs)
Keywords: MONOGRAPH REVIEW

KWDmonographreview
800630
M8060001

Copyright © 1980 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1980. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1980. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .